Drug Trial Radar · NCT00075829
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
Last checked: Nov 20, 2026Latest source record: Nov 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
710
Actual
Start
Dec 2003
Primary completion
Jun 2012
Study completion Mar 2013
Sponsor
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)NIH
- Sponsor type
- NIH
- Collaborators
- Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI); National Marrow Donor Program
- First posted
- Jan 13, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is designed as a Phase III, multi-center trial of tandem autologous transplants versus the strategy of autologous followed by Human Leukocyte Antigen (HLA)-matched sibling non-myeloablative allogeneic transplant. Study subjects will be biologically assigned to the appropriate arm depending on the availability of an HLA-matched sibling. There is a nested randomized phase III trial of observation versus maintenance therapy following the second autologous transplant for patients on the tandem autologous transplant arm.
Conditions
- Multiple Myeloma
Interventions
One Autologous TransplantProcedure
Melphalan will be administered at a dose of 200 mg/m2. Melphalan will be given in one dose infused on Day -2. Melphalan dose is based on ideal body weight (IBW) for patients who weigh 100-120% of their IBW. All patients will receive an autologous graft with a minimum cell dose of 2.0 x 106 CD34+ cells/kg patient weight. Patients will receive \~5 ug/kg/day of Granulocyte-Colony Stimulating Factor (G-CSF) subcutaneously from Day 5 post-transplant until absolute neutrophil count (ANC) \> 500/mm3 for two days.
Non-Myeloablative Allogeneic TransplantProcedure
Upon recovery and at least Day 60 post-autograft, patients with an available 6/6 HLA matched sibling will receive an allograft after non-myeloablative conditioning. Day 0 patients will receive Total Body Irradiation (TBI) 2.0 Gy from a linear accelerator ≤ 20 cGy/min, followed by allogeneic peripheral blood stem cell (PBSC) infusion. Commence cyclosporine (CSA) on Day -3 at 5 mg/kg bid PO for a daily dose of 10 mg/kg/day through Day +84 based on actual body weight. Starting on Day 84, patients in partial or complete response with the absence of graph versus host disease (GVHD) will have CSA tapered so the patient will be off CSA by Day 180. Oral administration of Mycophenolate Mofetil will be at a daily dose of 30 mg/kg/day from the evening of Day 0 until Day 27 post-transplant.
Second Autologous TransplantProcedure
Upon recovery from the first autograft, but at least 60 days (preferably between 60-120 days) after the first autograft, patients without an HLA-matched sibling donor will receive a second autograft, also conditioned with melphalan 200 mg/m2.
ThalidomideDrug
Patients will be initiated on a starting dose of 50 mg/day. The dose will be increased weekly by 50 mg as tolerated to achieve a target dose of 200 mg/day. Patients will be treated for 12 months with thalidomide.
DexamethasoneDrug
Patients will receive dexamethasone at a dose of 40 mg per day during Days 1-4 of each month for 12 months. The first dose of dexamethasone to be given the same day the patient starts thalidomide.
ObservationBehavioral
One year of observation post-transplants.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: Year 3
Locations
36 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
City of Hope Samaritan
Phoenix, Arizona
City of Hope National Medical Center
Duarte, California
Scripps Clinic/Green Hospital
La Jolla, California
UCSD Medical Center
La Jolla, California
Stanford Hospital and Clinics
Stanford, California
Colorado Blood Cancer Institute
Denver, Colorado
University of Florida College of Medicine (Shands)
Gainesville, Florida
Emory University
Atlanta, Georgia
BMT Group of Georgia/Northside Hospital
Atlanta, Georgia
Loyola University
Maywood, Illinois
IBMT (Indiana Blood and Marrow Transplant) at St Francis Franciscan Health
Indianapolis, Indiana
Wichita CCOP
Wichita, Kansas
Tufts - New England Medical Center
Boston, Massachusetts
DFCI/Brigham & Women's
Boston, Massachusetts
University of Michigan Medical Center
Ann Arbor, Michigan
University of Minnesota
Minneapolis, Minnesota
University of Nebraska Medical Center
Omaha, Nebraska
Hackensack University Medical Center
Hackensack, New Jersey
Memorial Sloan-Kettering Cancer Center
New York, New York
Duke University Medical Center
Durham, North Carolina
Jewish Hospital BMT Program
Cincinnati, Ohio
University Hospitals of Cleveland/Case Western
Cleveland, Ohio
University of Oklahoma Medical Center
Oklahoma City, Oklahoma
Oregon Health Sciences University (A)
Portland, Oregon
University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania
Fox Chase - Temple University - BMT Program
Philadelphia, Pennsylvania
Vanderbilt University
Nashville, Tennessee
Baylor College of Medicine/The Methodist Hospital
Houston, Texas
University of Texas/MD Anderson Cancer Research Center
Houston, Texas
Texas Transplant Institute
San Antonio, Texas
Utah BMT/Univ of Utah Med School
Salt Lake City, Utah
Virginia Commonwealth University MCV Hospitals
Richmond, Virginia
Fred Hutchinson Cancer Research Center
Seattle, Washington
University of Wisconsin Hospitals & Clinics
Madison, Wisconsin
Medical College of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.